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infection possibilities were improved. The shrinkage of services of the district hospitals 
had attracted decision-makers’ attention, some measures were adopted. Future inpact 
is yet to be studied.
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OBJECTIVES: To determine the less costly alternative of parenteral nutrition in Public 
Health Care Institutions in Mexico. METHODS: A cost-minimization study was per-
formed comparing the use of RTU (considering four different formulations with 3.6 g, 
6.6 g, 11.2 g and 13.2 g of nitrogen) against equivalent CNF preparations made by a 
third-part company. This study compared all direct and indirect costs considering an 
institutional perspective based on data collected from the main Public Health Institu-
tion in Mexico. Costs associated with third-part services were estimated within a
Monte Carlo Simulation. Costs of the equivalent RTU TPN bags were obtained from 
a manufacturer. Results were evaluated with a Student t-test considering the mean use 
of 20 bags a day in order to evaluate if there is any signiﬁ cant differences between
the costs of in-hospital and third-part companies preparations for long-term use of 
TPN. RESULTS: Third-part services costs showed a triangular distribution according
to Monte Carlo results. RTU costs were 9.95%, 16.93%, 36.45% and 27.21% lower 
than CNF TPN for preparations with 3.6 g, 6.6 g, 11.2 g and 13.2 g of nitrogen 
respectively. T-test showed a signiﬁ cant difference in favor of RTU TPN for all evalu-
ated formulations (p  0.0001 for all). CONCLUSIONS: The use of RTU offers a 
signiﬁ cant less costly alternative for adult TPN when compared with equivalent third-
part CNF in Public Health Institutions in Mexico. The long-term adoption of the RTU 
TPN system can be associated with important cost-savings for public health institu-
tions in Mexico.
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OBJECTIVES: To identify and categorize publicly available cases of performance-
based health outcomes agreements. METHODS: We performed a systematic review 
of performance-based health outcomes agreements over the past 20 years (July 1998 
–October 2008) using publicly available databases and input from colleagues and
health care experts. We further developed a taxonomy of agreement types by induc-
tively organizing the cases identiﬁ ed according the timing, execution, and health out-
comes measured in the agreements. RESULTS: Our search yielded in excess of 60 
documents including peer reviewed articles, secondary publications, websites and in-
person communications. From this set, we identiﬁ ed 28 agreements categorized as 
coverage with evidence development, eight that were categorized as conditional treat-
ment continuation, and ten agreements categorized as performance-linked reimburse-
ment. Because of current national reimbursement policies, devices appear to be the 
best candidates in the US, whereas pharmaceuticals appear to the best candidates for 
EU and other non US payers. CONCLUSIONS: With a relatively small number of 
cases from which to draw conclusions, it is difﬁ cult to ascertain whether performance-
based health outcomes agreements signal a fundamental change in reimbursement
policies. Given the interest to date and the potential to meet the goals of interested 
stakeholders, these agreements have the potential to become more common in health
care. However, signiﬁ cant challenges including high transaction costs and insufﬁ cient 
information systems may limit the long-term impact and viability of health outcomes
based agreements. Future studies regarding the attitudes and perceptions of various 
stakeholders are needed, as well as evaluations of the results and experience with the
agreements implemented thus far.
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OBJECTIVES: The ISPOR Task Force for Good Research Practices for Measuring
Drug Costs in Cost-Effectiveness Analyses recently vetted a draft report suggesting 
that costs from a payer perspective be net all copayments. Our objective is to highlight 
the impact and challenges of including patient cost sharing in cost-effectiveness analy-
ses. METHODS: We used a 1-year decision model to calculate the incremental cost-
effectiveness ratio (ICER) of a biologic from the payer perspective. The biologic plus
usual care was compared to usual care. Effects and costs were taken from the litera-
ture. We assumed 50% of plans covered biologics as coinsurance and 50% as copay-
ments. The maximum coinsurance was assumed to be $2500. We assumed that 20% 
of the maximum coinsurance was attributable to the biologic. We assumed the average 
coinsurance for a biologic was 20% and the average copayment was $50. Sensitivity 
analyses were performed. RESULTS: The ICER was $114,813/QALY without 
accounting for patient cost sharing. With cost sharing the biologic drug cost was 4%
lower with an ICER of $98,144/QALY. Sensitivity analysis showed that a 5% increase 
in the rebate has a larger effect on the ICER than cost sharing. The amount of coinsur-
ance attributable to the treatment had the largest effect on cost sharing. CONCLU-
SIONS: Cost sharing does not affect the ICER when the copayment is ﬁ xed and
remains constant for all comparators. Data exists within plans to update inputs for 
many of our assumptions. Patient coinsurance levels should be assessed without the 
biologic in order to determine whether excess coinsurance could be attributed to the
biologic (drug of interest). Cost sharing should not be included if patients reach their 
maximum coinsurance without treatment. This analysis did not consider cost sharing 
associated with non-drug costs, which may increase the ICER due to more cost offsets 
for the biologic comparator.
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OBJECTIVES: We evaluated the ﬁ rst-year operation of Korean positive list system for 
pharmaceutical reimbursement through analyzing decisions accomplished by Drug 
Reimbursement Evaluation Committee (DREC) since we introduced this system in 
December 2006. METHODS: Ninety-four decisions made by DREC till October 2008 
were included in this analysis. Variables concerned in reimbursement decisions were
selected and regression analysis was carried out to explores which variables are likely 
to lead positive recommendations. RESULTS: DREC decided 54(57.4%) products to
be listed among total of 94 decisions. New molecular entity drugs and orphan drugs
account for 44.7% and 18.1% of all included drugs. Lack of evidence to prove cost-
effectiveness was the most common reason which lead negative recommendation (N 
 26, 65%) followed by lack of evidence for clinical effectiveness (N  5, 12.5%) and 
for both of them (N  4, 10%). In terms of clinical aspect, the number of RCT, Ana-
tomical Therapeutic Chemical (ATC) classiﬁ cation and orphan drugs did not have
signiﬁ cant inﬂ uence on the odds of positive decisions(p  0.05) except for improved 
extent of clinical beneﬁ t compared with comparators (p  0.001). In other aspects,
less medical cost was a positive factor and additional budget impact was a negative 
factor in relation to recommendation (p  0.001). CONCLUSIONS: Lack of evidence 
for cost-effectiveness was the most common reason to lead negative recommendation. 
Many clinical factors which we considered seemed not to be signiﬁ cantly associated 
with recommendations in Korea. DREC recently decided reference range of cost-
effectiveness threshold reﬂ ecting disease severity, social burden, quality of life and 
aspect of renovation after in-depth discussions. According to newly established crite-
ria, evaluation would be conducted comprehensively in decision making for pharma-
ceutical reimbursement.
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OBJECTIVES: To examine associations between health status and attitude about
health insurance in Medical Expenditure Panel Survey population (MEPS). Studies
have shown that lack of health insurance is associated with important clinical
characteristics, including use of fewer health care services, delaying-seeking medical 
care and forgoing necessary care for potentially serious symptoms. METHODS:
The Household Component (HC) public use ﬁ le from the 2005 MEPS data, a nation-
ally representative survey of the noninstitutionalized population was used in the
United States. Health status and attitudes towards health insurance were measured 
using the Self-Administered Questionnaire (SAQ) data collected within MEPS.
Data were analyzed using SAS 9.1.3. Descriptive statistics were obtained using 
PROC UNIVARIATE. PROC CANCORR was used to measure canonical correlation
between set of attitude about health insurance variables and set of health status 
variables. RESULTS: The mean age of sample was 46.33 years (Standard deviation:
17.69). the majority were female 60.6% and white 77.2%. The ﬁ rst canonical cor-
relation was 0.32 (11% overlapping variance); the second was 0.08 (0.6% overlapp-
ing variance). All four pairs of canonical variates accounted for the signiﬁ cant
relationships between the two sets of variables. Canonical Redundancy Analysis 
obtained using PROC CANCORR found ﬁ rst health status variate accounting 4% 
of variance in attitude about health insurance variable set. CONCLUSIONS: A per-
son’s health status and their attitude about health insurance are moderately related. 
Further studies need to be conducted with more measures of attitude about health 
insurance to determine exact relationship between health status and attitude about 
health insurance.
